|
Variables
|
Strategic treatment (n=17)
|
Mismatched (n=17)
|
p value
|
|---|
|
Age (years)
|
53.2±16.0
|
58.4±10.8
|
0.5016
|
|
Male, n (%)
|
12 (70.5)
|
6 (35.3)
|
0.0084
|
|
Disease duration (months)
|
|
PSO
|
108 (42, 288)
|
216 (10, 258)
|
0.9176
|
|
PsA
|
42 (13.5, 116.5)
|
43 (16.5, 144)
|
0.7960
|
|
Peripheral arthritis
|
17 (100)
|
17(100)
|
1.0000
|
|
Spinal involvement
|
4 (23.5)
|
6 (35.2)
|
0.7080
|
|
History of past bDMARDs
|
1st 12 (70.5)
|
1st 12 (70.5)
|
1.0000
|
|
Concomitant MTX use
|
12 (70.6)
|
10 (58.8)
|
0.7270
|
|
bDMARDS initiated
|
|
IL-17-i/TNF-i
|
6 (35.2)/11 (64.7)
|
8 (47.0)/9 (52.9)
|
0.4905
|
|
Disease activity
|
|
TJC
|
7 (5, 8.5)
|
8 (3.5, 14)
|
0.4164
|
|
SJC
|
6 (4, 12.5)
|
5 (2.5, 7)
|
0.1453
|
|
CRP (mg/dl)
|
0.99 (0.18, 2.14)
|
0.54 (0.075, 1.71)
|
0.2347
|
|
DAPSA
|
24.1 (19.2, 33.7)
|
31.2 (20.9, 39.8)
|
0.1848
|
|
PASI
|
3.1 (0.5, 5.75)
|
1.6 (0.4, 6.3)
|
0.7823
|
- Data are expressed as mean ± standard deviation, median (interquartile range [IQR]), or number (%)
- TNF-i TNF inhibitors, IL-17-i IL-17 inhibitors, TJC tender joint counts 68, SJC swollen joint counts 66, DAPSA Disease Activity in Psoriatic Arthritis, PASI Psoriasis Area and Severity Index
- *p<0.05, by Mann-Whitney U test or chi-square test
